公开(公告)号：US20250122299A1

公开(公告)日：2025-04-17

申请号：US18818199

申请日：2024-08-28

Applicant: Xencor, Inc. ,  Janssen Biotech, Inc.

Inventor： Gregory L. Moore ,  Michael Hedvat ,  Matthew Adam Dragovich ,  Lorena Fontan Gabas ,  Adam Zwolak ,  Ulrike Philippar ,  Pankaj Seth ,  Nele Vloemans ,  Ivo Cornelissen

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: Provided herein are novel anti-CD20 x anti-CD28 antibodies and methods of using such antibodies for the treatment of B-cell malignancies. Subject anti-CD20 x anti-CD28 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and CD20 on tumor cells. Thus, such antibodies enhance anti-tumor activity at tumor sites. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3 x anti-CD20 x anti-CD79b antibodies) for the treatment of B-cell malignancies.

公开(公告)号：US20240218082A1

公开(公告)日：2024-07-04

申请号：US18440860

申请日：2024-02-13

Applicant: Xencor, Inc. ,  Janssen Biotech, Inc.

Inventor： John R. Desjarlais ,  Gregory Moore ,  Michael Hedvat ,  Juan Diaz ,  Veronica Gusti Zeng ,  Matthew Adam Dragovich ,  Joseph Erhardt ,  Theresa McDevitt ,  Fouad Moussa ,  Pankaj Seth ,  Fei Shen ,  Adam Zwolak

IPC: C07K16/46 ,  C07K16/28 ,  C07K16/30

CPC classification number: C07K16/468 ,  C07K16/2818 ,  C07K16/3069 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/622

Abstract: Provided herein are novel anti-CD28 x anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28 x anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3 x anti-PSMA antibodies) for the treatment of prostate cancers.

公开(公告)号：US20230322961A1

公开(公告)日：2023-10-12

申请号：US18311771

申请日：2023-05-03

Applicant: Xencor, Inc. ,  Janssen Biotech, Inc.

Inventor： John R. Desjarlais ,  Gregory Moore ,  Michael Hedvat ,  Juan Diaz ,  Veronica Gusti Zeng ,  Matthew Adam Dragovich ,  Joseph Erhardt ,  Theresa McDevitt ,  Fouad Moussa ,  Pankaj Seth ,  Fei Shen ,  Adam Zwolak

IPC: C07K16/46

CPC classification number: C07K16/468 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/622

Abstract: Provided herein are novel anti-CD28×anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28×anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3×anti-PSMA antibodies) for the treatment of prostate cancers.

公开(公告)号：US20240158499A1

公开(公告)日：2024-05-16

申请号：US18549665

申请日：2022-03-11

Applicant: JANSSEN BIOTECH, INC.

Inventor： Songmao Zheng ,  John Emery ,  Jennifer F. Nemeth ,  Fang Shen ,  Pankaj Seth

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/622

Abstract: The invention provides antigen binding domains that bind Cluster of Differentiation 79B protein (CD79B) protein comprising the antigen binding domains that bind CD79b, polynucleotides encoding them, vectors, host cells, methods of making and using them.

公开(公告)号：US20230265218A1

公开(公告)日：2023-08-24

申请号：US18172987

申请日：2023-02-22

Applicant: Xencor, Inc. ,  Janssen Biotech, Inc.

Inventor： John R. Desjarlais ,  Gregory Moore ,  Michael Hedvat ,  Juan Diaz ,  Veronica Gusti Zeng ,  Matthew Adam Dragovich ,  Joseph Erhardt ,  Theresa McDevitt ,  Fouad Moussa ,  Pankaj Seth ,  Fei Shen ,  Adam Zwolak

IPC: C07K16/46

CPC classification number: C07K16/468 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/622

Abstract: Provided herein are novel anti-CD28×anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28×anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3×anti-PSMA antibodies) for the treatment of prostate cancers.